We have recently been working on a mechanistic PBPK/PD model to study dabigatran reversal, which includes the reversal of dabigatran by hemodialysis and its antidote idarucizumab.
Therefore, a PBPK model of idarucizumab has been carefully developed and evaluated. The model was then coupled with a recently published PBPK model of dabigatran to predict the interaction of both compounds. The dabigatran model was furthermore extended by a dialyzer compartment and a hemodialysis clearance as well as by a simple PD model.
Dear OSP-community,
We have recently been working on a mechanistic PBPK/PD model to study dabigatran reversal, which includes the reversal of dabigatran by hemodialysis and its antidote idarucizumab.
Therefore, a PBPK model of idarucizumab has been carefully developed and evaluated. The model was then coupled with a recently published PBPK model of dabigatran to predict the interaction of both compounds. The dabigatran model was furthermore extended by a dialyzer compartment and a hemodialysis clearance as well as by a simple PD model.
Related publications: Fuhr LM, Hanke N, Meibohm B, Lehr T Effective Removal of Dabigatran by Idarucizumab or Hemodialysis: A Physiologically Based Pharmacokinetic Modeling Analysis Clinical Pharmacokinetics 2020
All models can be found here.
Best regards, Laura